Italy vs Tonga: The number of people with susceptibility test result for rifampicin
Italy
115.63
in 2021
Tonga
100
in 2021
Italy rank
1st
Tonga rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Italy
- Tonga
How they compare
Italy currently reports 115.63 against 100 in Tonga, a difference of 15.63.
That makes Italy's figure about 1.2 times Tonga's.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Italy ahead.
Italy ranks 1st and Tonga ranks 2nd of 146 countries.
Italy has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Italy | Tonga | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 105.53 | 100 | 5.53 | Italy |
| 2020s | 117.07 | 100 | 17.07 | Italy |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Italy or Tonga?
- Italy, at 115.63 against 100 in Tonga as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Italy and Tonga?
- 15.63, with Italy ahead.
- How many years of comparable data are there for Italy and Tonga?
- 5 years are reported by both, from 2017 to 2021.
- How do Italy and Tonga rank globally for the number of people with susceptibility test result for rifampicin?
- Italy ranks 1st and Tonga ranks 2nd of 146 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.